PMV Pharmaceuticals, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter earnings release.
Business context
PMV is a clinical-stage precision oncology company with no approved products and no product revenue. Its lead candidate, PC14586 (rezatapopt), is an oral therapy designed to correct the p53 Y220C mutation. The company is pursuing a tumor-agnostic strategy; its other programs remain in discovery or preclinical development. PMV reported that it owns worldwide commercial rights to its programs.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $55.9 million | $52.0 million |
| General and administrative expense | $24.2 million | $25.1 million |
| Total operating expenses | $80.1 million | $77.0 million |
| Interest income, net | $11.2 million | $3.6 million |
| Net loss | $69.0 million | $73.3 million |
| Net loss per share, basic and diluted | $1.44 | $1.61 |
| Cash used in operating activities | $55.7 million | $63.8 million |
- At December 31, 2023, cash and cash equivalents were $37.7 million and marketable securities were $190.9 million, for total cash, cash equivalents and marketable securities of $228.6 million, versus $243.5 million a year earlier.
- Working capital was $193.4 million; total assets were $252.2 million, total liabilities $26.5 million, and stockholders’ equity $225.7 million. Liabilities included $13.3 million of operating lease liabilities. The filing reports no borrowings or other financial debt.
- There was no meaningful product gross margin because PMV had no product sales. The filing does not present a product margin measure.
Material changes versus 2022
- Net loss narrowed by $4.4 million, principally as net interest income rose by $7.5 million amid higher interest rates; operating expenses increased by $3.1 million.
- R&D expense increased $3.9 million, mainly from higher personnel and stock-based compensation, partly offset by lower research and development contractor costs. G&A expense declined $0.8 million, primarily due to lower insurance and facility costs.
- Operating cash use decreased by $8.1 million. Investing cash outflow increased to $50.5 million, largely reflecting net purchases of marketable securities. Financing cash inflow was $35.6 million, primarily from ATM share sales.
- PMV sold 5.15 million shares through its at-the-market program at a weighted average price of $6.97 per share, generating $35.1 million net proceeds. About $113.8 million of gross ATM capacity remained at year-end. Shares issued and outstanding rose to 51.45 million from 45.77 million.
Development, outlook and risks
- At the September 5, 2023 data cutoff, 67 patients with p53 Y220C mutations had enrolled in the PC14586 monotherapy trial. Among 38 evaluable patients with measurable disease who were KRAS wild type and treated in the reported efficacious dose range, 13 (34%) had confirmed partial responses by investigator assessment. At the recommended Phase 2 dose, 6 of 16 patients (38%) had confirmed partial responses. These are early clinical results from a trial in progress, not confirmatory evidence of efficacy.
- PMV reported general tolerability in the trial; commonly reported adverse events included nausea, vomiting, AST/ALT increases, anemia, increased blood creatinine and fatigue. It opened a Phase 1b combination arm with Merck’s KEYTRUDA in December 2022, with approximately 36 patients expected to enroll.
- Following a July 2023 End-of-Phase-1 meeting, PMV said it reached alignment with the FDA on the recommended Phase 2 dose and key design elements for the registrational study. The pivotal Phase 2 monotherapy portion was planned to start in the first quarter of 2024. PC14586 has FDA Fast Track designation; neither designation nor the planned study guarantees approval.
- Management estimated that year-end cash, cash equivalents and marketable securities would fund planned operations at least into the second half of 2026. This estimate depends on assumptions and may change; PMV expects continued losses and may need additional financing. It had an accumulated deficit of $310.0 million.
- In January 2024, after year-end, PMV announced a workforce reduction of approximately 30%, intended to streamline operations and preserve capital as PC14586 advances. The reduction was expected to be substantially complete by June 30, 2024 and fully complete by the end of the third quarter. Estimated nonrecurring charges were $1.0–$1.4 million, mostly cash costs.
- Principal risks include reliance on PC14586, clinical and regulatory uncertainty, limited ability to recruit patients with the targeted mutation, dependence on third-party manufacturers and research providers, companion-diagnostic requirements, competition, intellectual-property risks, and potential need for further capital. Certain development and raw-material sourcing activities rely on third parties in China.
- The Princeton headquarters lease runs through 2032; disclosed future lease payments were $16.8 million before present-value adjustment. PMV reported no material legal proceedings as of February 29, 2024. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2023; the auditor did not audit internal control effectiveness.
Important facts for investors to verify
- Updated, mature clinical results—including response durability, safety, patient numbers and the registrational Phase 2 outcomes—against the preliminary, investigator-assessed data in this filing.
- Whether Phase 2 started as planned in Q1 2024, and any subsequent FDA feedback on study design, endpoints or the potential for accelerated approval.
- Actual cash use and runway after the restructuring, trial expansion and related costs; the estimate of funding into the second half of 2026 is management’s projection.
- ATM share issuance, remaining capacity and resulting dilution, alongside any future financing needs.
- Progress and enrollment in the KEYTRUDA combination arm, and the availability and regulatory path for any required companion diagnostic.